DPDiego Pedrero

Diego Pedrero

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Diego Pedrero has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Vascular and Circulating Blood Exposure to Proton or Photon Irradiation: Differentials in Lymphocyte Subset Metrics in Cancer Patients

    by Rosa Meiriño, Felipe A. Calvo, Enrique Amaya, Javier Burguete, Javier Serrano, Marina García Cardosa, Diego Pedrero, Diego Azcona, Jacobo Palma, María A. Fortuño, et al.

    Background/Objectives: Radiation-induced lymphopenia is consistently associated with adverse outcomes across solid tumours, yet the vascular compartment that carries the irradiated lymphocyte pool is not routinely delineated during treatment planning. The VASA project makes blood vessels an explicit, measurable structure in that process. Phase II aimed primarily to establish the feasibility of that delineation and secondarily to explore how dose–volume metrics computed on MRI-segmented vessels relate to serial immunophenotyping in patients treated with protons or photons. Methods: Thirty-nine patients treated between March 2021 and May 2022 were studied prospectively (30 proton, 9 photon). Flow-contrast three-dimensional MRI with three velocity-encoding directions was added to simulation; vessel masks segmented semi-automatically from the sum-of-magnitude reconstruction were imported into the treatment-planning system to generate dose–volume histograms. The effective dose to circulating immune cells (EDIC), the integral dose to vessels (IDVe) and the integral dose to target were computed. Blood was sampled at the start and at the end of irradiation for lymphocyte counts and B, T and NK immunophenotyping. Groups were compared with Welch’s t-test for continuous variables and Fisher’s exact test for categorical variables, without correction for multiple comparisons; the photon subgroup was not matched. Results: EDIC was higher with photons than protons (5.60 vs. 1.25 Gy; p = 0.005) and in patients who became lymphopenic (4.84 vs. 1.47 Gy; p = 0.027); IDVe differed in the same direction without reaching significance (3.60 vs. 0.53 Gy·L, p = 0.091; 3.08 vs. 0.67 Gy·L, p = 0.180). Within the proton cohort, EDIC and IDVe increased from brain to head-and-neck to thorax–abdomen targets (0.81, 1.11 and 2.17 Gy; 0.13, 0.26 and 1.63 Gy·L), and the IDVe ordering persisted after adjustment for target volume (p < 0.001). Lymphocyte counts fell from 1.92 to 1.43 × 103/µL in the proton cohort (p < 0.001), with the lowest end-of-treatment values in thorax–abdomen targets (1.31 × 103/µL). B, T and NK subpopulations all declined in the proton cohort; among regions, only head-and-neck targets showed significant T and NK losses. Conclusions: Patient-specific vascular delineation and dosimetry are feasible in a clinical planning workflow, and the resulting metrics track irradiation modality and the magnitude of lymphocyte depletion. These associations are exploratory; immune-sparing plan optimisation using vascular constraints remains a future application requiring prospective validation.

  • Open Access

    Vascular and Circulating Blood Exposure to Proton or Photon Irradiation: Differentials in Lymphocyte Subsets Metrics in Cancer Patients

    by Rosa Meiriño, Felipe A. Calvo Manuel, Enrique Amaya, Javier Burguete, Javier Serrano, Marina García Cardoso, Diego Pedrero, Diego Azcona, Jacobo Palma, María Antonia Fortuño, et al.

    Background/Objectives: Radiation-induced lymphopenia is consistently associated with adverse outcomes across solid tumours, yet the vascular compartment that carries the irradiated lym-phocyte pool is not common delineated during treatment planning. The VASA project makes blood vessels an explicit, measurable structure in that process. We report Phase II, relating dose–volume metrics computed on MRI-segmented vessels to serial immunophenotyping in patients treated with protons or photons. Methods: Forty-three patients treated between March 2021, and May 2022 were studied prospectively (35 proton, 8 photon). Flow-contrast three-dimensional MRI with three velocity-encoding directions was added to simulation; the sum-of-magnitude recon-struction was used for semi-automated vessel segmentation, and vessel masks were imported into the treatment planning system to generate dose–volume histograms. The effective dose to circu-lating immune cells (EDIC), the integral dose to vessels (IDVe) and the integral dose to target were computed. Blood was sampled at the start, middle and end of irradiation for lymphocyte counts and B, T and NK immunophenotyping. Results: EDIC and IDVe were higher with photons than protons (6.10 vs. 1.22 Gy; 3.6 vs. 0.5 Gy·L) and higher in patients who became lymphopenic than in those who did not (4.2 vs. 1.1 Gy; 2.7 vs. 0.37 Gy·L). Within the proton cohort, EDIC and IDVe increased from brain to head-and-neck to thorax–abdomen targets (0.80, 1.11 and 1.89 Gy; 0.15, 0.26 and 1.31 Gy·L; p < 0.05). Lymphocyte counts fell from 1.81 to 1.42 × 10³/µL overall (p < 0.05), with the lowest nadir in thorax–abdomen targets (0.90 × 10³/µL). B, T and NK subpopula-tions all declined; T and NK losses were greatest in head-and-neck targets. Conclusions: Vascular dose can be measured patient by patient and tracks both irradiation modality and the magnitude of lymphocyte depletion. Treating vessels and circulating blood as an organ at risk is feasible and offers a route to immune-sparing radiotherapy plan optimisation.

  • Open Access

    Salvage Proton Therapy Re-Irradiation in Recurrent Head and Neck Cancer: Outcomes and Adverse Events by Re-Irradiated Target Site

    by Enrique Amaya, Jacobo Palma, Roser Fayós-Solà, Rosa Meiriño, Mauricio Cambeiro, Ana Navarrete, Pablo Cabello-García, Alberto Viñals, Diego Pedrero, Felipe A. Calvo, et al.

    Background/Objectives: Photon re-irradiation in previously treated head and neck cancer (HNC) is constrained by cumulative normal-tissue toxicity. Pencil-beam scanning intensity-modulated proton therapy (PBS-IMPT) allows for a sharper dose conformation than conventional photon techniques, which may widen the therapeutic window in previously irradiated tissue. Methods: Sixty-five patients with recurrent or second primary HNC were enrolled in a prospective single-institution registry and re-irradiated with PBS-IMPT between January 2020 and December 2025. Forty-five were treated with radical intent (69.2%), and 20 were treated postoperatively (30.8%), with a median prescribed dose of 66 Gy (RBE) in 30 fractions. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Locoregional control (LRC), adverse events and the prognostic impact of anatomical extent were secondary endpoints. Results: The median follow-up was 9.3 months. The median OS was 17.2 months (95% CI 13.9–NR), with a 12-month rate of 67.1%. The median PFS was 10.1 months and the median LRC was 28.1 months. Central/skull-base involvement was associated with a non-significant trend toward worse OS (14.3 vs. 35.2 months; p = 0.062) and with significantly worse PFS (9.1 vs. 14.7 months; p = 0.037) than peripheral disease, but LRC did not differ between the groups (p = 0.240). Grade ≥ 3 oral mucositis occurred in 7.7%, with no grade 4–5 acute events. Within a median follow-up of 9.3 months, late osteoradionecrosis affected 6.2%, but late toxicity data remain preliminary given the short follow-up. Ninety-two percent of patients completed treatment. Conclusions: PBS-IMPT re-irradiation provided adequate survival with low acute toxicity. T3–T4 stage at re-irradiation was the only variable retaining significance for PFS on multivariable analysis (HR 4.32, 95% CI 1.24–15.13; p = 0.022). The poor survival observed for central/skull-base disease on Kaplan–Meier curves disappeared after T-stage adjustment, indicating the higher concentration of advanced disease in that compartment. Multicentre prospective data and longer follow-up are needed.